X
[{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Alembic Pharmaceuticals Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Announces Its Joint Venture Aleor Dermaceuticals Receives USFDA Final Approval for Mupirocin Cream USP, 2%","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Mupirocin
Filters
Companies By Therapeutic Area
Details:
Mupirocin cream USP, 2% is indicated for the treatment of secondarily infected traumatic skin lesions due to susceptible strains of S. aureus and S. pyogenes.
Lead Product(s):
Mupirocin
Therapeutic Area: Infections and Infectious Diseases
Product Name: Mupirocin
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Alembic Pharmaceuticals Limited
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 17, 2021